The presence of tertiary lymphoid structures (TLS) in tumor tissues may predict the patients with advanced non-small cell lung cancer (NSCLC) who will benefit most from treatment with atezolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results